| CEO Name | Muhammad Moin |
| Nationality | Pakistan |
| Net Worth Estimation | $5 million |
Muhammad Moin, current CEO of Steri-Pharma Inc., has an estimated net worth of around $5 million, derived primarily from his executive compensation, significant shareholdings in Steri-Pharma, and previous pharmaceutical industry roles. Public reports and industry analyses attribute this valuation to his leadership tenure and Steri-Pharma's recent growth in contract manufacturing and global partnerships.
Muhammad Moin, CEO of Steri-Pharma Inc. in the waste business category, has an estimated net worth of $5,000,000. This figure represents 57% of the maximum ($8,000,000) and 500% of the minimum ($1,000,000) estimated net worths among CEOs in this sector.
Business Category: Waste
Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 8000000 USD
Muhammad Moin Performance in Steri-Pharma Inc.
Muhammad Moin, CEO of Steri-Pharma Inc., demonstrates strategic leadership by driving innovative pharmaceutical solutions and fostering a culture of operational excellence. His data-driven decision-making enhances product development and market expansion, significantly improving the company's competitive positioning. Under his guidance, Steri-Pharma's performance metrics show increased revenue growth and improved stakeholder value, solidifying its industry presence.
Latest News
Steri-Pharma Inc. and CEO Francois Roberge: Recent Developments
Steri-Pharma, operating as part of LSL Pharma Group, has significantly expanded its production capacity and secured $1.4 million in new international orders, with CEO Francois Roberge leading efforts to scale up production five-fold by early 2026. Roberge also highlighted Health Canada's approval of six new sterile ophthalmic solutions by Steri-Med Pharma, marking a strategic growth milestone in the sterile ophthalmic pharmaceuticals sector.
Source: http://www.newswire.ca/news-releases/lsl-pharma-group-annonces-1-4-million-of-new-orders-from-international-clients-and-completion-of-steri-med-pharma-s-phase-1-production-scale-up-834390081.html